Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

Takeda's ALK inhibitor meets primary endpoint in interim analysis from critical first-line lung cancer head-to-head study, helping validate Ariad acquisition, but will be a relative class latecomer to the setting.  

Cancer cells on scientific background.3d illustration
PROMISING RESULTS FOR BRIGATINIB IN FIRST-LINE NSCLC • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.'s oral anaplastic lymphoma kinase (ALK) inhibitor brigatinib has shown progression-free survival (PFS) benefits over close rival crizotinib in the first interim analysis from an ongoing head-to-head trial in the commercially important first-line lung cancer setting.

While the Japanese firm did not disclose details of the top-line findings, it said the first pre-specified interim analysis from...

More from Anticancer

More from Therapy Areas

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.